Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223.

Roviello G, Gallicchio R, Bozza G, Rodriquenz MG, Aieta M, Storto G.

Onco Targets Ther. 2018 Dec 17;12:9-13. doi: 10.2147/OTT.S174206. eCollection 2019.

2.

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators.

Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.

PMID:
27473888
3.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C.

Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13.

PMID:
24836273
4.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C.

Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7. Epub 2014 Oct 17.

PMID:
25439694
5.

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.

Vogelzang NJ.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):809-819. doi: 10.1080/17512433.2017.1345624. Epub 2017 Jul 3. Review.

PMID:
28649893
6.

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H.

Int J Clin Oncol. 2018 Feb;23(1):173-180. doi: 10.1007/s10147-017-1176-0. Epub 2017 Aug 2.

7.

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.

Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729-2. doi: 10.1016/j.eururo.2018.09.040. [Epub ahead of print]

PMID:
30293905
8.

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo Perez JM, Wagner V, Li R, Nordquist LT.

Ann Oncol. 2017 Oct 1;28(10):2464-2471. doi: 10.1093/annonc/mdx331.

9.

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D.

Eur Urol. 2016 Nov;70(5):875-883. doi: 10.1016/j.eururo.2016.06.002. Epub 2016 Jun 22.

10.
11.

Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.

McGann S, Horton ER.

Ann Pharmacother. 2015 Apr;49(4):469-76. doi: 10.1177/1060028014565444. Epub 2015 Jan 8. Review.

PMID:
25573268
12.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020. [Epub ahead of print]

13.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F.

BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.

14.

[Radium-223 dichloride in patients with castration-refractory prostate cancer].

Winter BM, von Rundstedt FC, Grimm MO.

Urologe A. 2017 Nov;56(11):1435-1439. doi: 10.1007/s00120-017-0514-1. Review. German.

PMID:
29022046
15.

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.

Uemura H, Uemura H, Matsubara N, Kinuya S, Hosono M, Yajima Y, Doi T.

Int J Clin Oncol. 2017 Oct;22(5):954-963. doi: 10.1007/s10147-017-1130-1. Epub 2017 May 6.

16.

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice.

Prelaj A, Rebuzzi SE, Buzzacchino F, Pozzi C, Ferrara C, Frantellizzi V, Follacchio GA, Civitelli L, De Vincentis G, Tomao S, Bianco V.

Oncol Lett. 2019 Feb;17(2):1467-1476. doi: 10.3892/ol.2018.9785. Epub 2018 Nov 30.

17.

Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.

Fosbøl MØ, Petersen PM, Daugaard G, Holm S, Kjaer A, Mortensen J.

Ann Nucl Med. 2018 Jan;32(1):16-21. doi: 10.1007/s12149-017-1212-1. Epub 2017 Oct 3.

PMID:
28975586
18.

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.

Carles J, Castellano D, Méndez-Vidal MJ, Mellado B, Saez MI, González Del Alba A, Perez-Gracia JL, Jimenez J, Suárez C, Sepúlveda JM, Manneh R, Porras I, López C, Morales-Barrera R, Arranz JÁ.

Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139. doi: 10.1016/j.clgc.2018.07.013. Epub 2018 Jul 21.

PMID:
30104161
19.

A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.

Küronya Z, Sinkovics I, Ágoston P, Bíró K, Bodrogi I, Böde I, Dank M, Gyergyay F, Vajdics T, Kolonics Z, Nagyiványi K, Rúzsa Á, Géczi L.

Pathol Oncol Res. 2017 Oct;23(4):777-783. doi: 10.1007/s12253-017-0190-x. Epub 2017 Jan 10.

PMID:
28074331
20.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Epub 2014 Sep 17. Review.

Supplemental Content

Support Center